6LXY

IRAK4 in complex with inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.19 Å
  • R-Value Free: 0.231 
  • R-Value Work: 0.201 
  • R-Value Observed: 0.202 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis.

Nair, S.Kumar, S.R.Paidi, V.R.Sistla, R.Kantheti, D.Polimera, S.R.Thangavel, S.Mukherjee, A.J.Das, M.Bhide, R.S.Pitts, W.J.Murugesan, N.Dudhgoankar, S.Nagar, J.Subramani, S.Mazumder, D.Carman, J.A.Holloway, D.A.Li, X.Fereshteh, M.P.Ruepp, S.Palanisamy, K.Mariappan, T.T.Maddi, S.Saxena, A.Elzinga, P.Chimalakonda, A.Ruan, Q.Ghosh, K.Bose, S.Sack, J.Yan, C.Kiefer, S.E.Xie, D.Newitt, J.A.Saravanakumar, S.P.Rampulla, R.A.Barrish, J.C.Carter, P.H.Hynes Jr., J.

(2020) ACS Med Chem Lett 11: 1402-1409

  • DOI: https://doi.org/10.1021/acsmedchemlett.0c00082
  • Primary Citation of Related Structures:  
    6LXY, 6VQL

  • PubMed Abstract: 

    IRAK4 is an attractive therapeutic target for the treatment of inflammatory conditions. Structure guided optimization of a nicotinamide series of inhibitors has been expanded to explore the IRAK4 front pocket. This has resulted in the identification of compounds such as 12 with improved potency and selectivity. Additionally 12 demonstrated activity in a pharmacokinetics/pharmacodynamics (PK/PD) model. Further optimization efforts led to the identification of the highly kinome selective 21 , which demonstrated a robust PD effect and efficacy in a TLR7 driven model of murine psoriasis.


  • Organizational Affiliation

    Biocon Bristol Myers Squibb Research Center, Bangalore 560099, India.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Interleukin-1 receptor-associated kinase 4A,
B,
C [auth D],
D [auth E]
305Homo sapiensMutation(s): 0 
Gene Names: IRAK4
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for Q9NWZ3 (Homo sapiens)
Explore Q9NWZ3 
Go to UniProtKB:  Q9NWZ3
PHAROS:  Q9NWZ3
GTEx:  ENSG00000198001 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9NWZ3
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Modified Residues  2 Unique
IDChains TypeFormula2D DiagramParent
SEP
Query on SEP
A,
B,
C [auth D],
D [auth E]
L-PEPTIDE LINKINGC3 H8 N O6 PSER
TPO
Query on TPO
A,
B,
C [auth D],
D [auth E]
L-PEPTIDE LINKINGC4 H10 N O6 PTHR
Binding Affinity Annotations 
IDSourceBinding Affinity
EXF Binding MOAD:  6LXY IC50: 3.4 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.19 Å
  • R-Value Free: 0.231 
  • R-Value Work: 0.201 
  • R-Value Observed: 0.202 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 135.67α = 90
b = 140.81β = 125.7
c = 86.28γ = 90
Software Package:
Software NamePurpose
HKL-2000data reduction
HKL-2000data scaling
BUSTERrefinement
PDB_EXTRACTdata extraction
MOLREPphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2020-11-25
    Type: Initial release